BioHarvest Sciences, Inc. · NASDAQ:BHST
BioHarvest Sciences — Investor Presentation (February 2023)
54 slides from BioHarvest Sciences's investor presentation, Feb 12, 2023
Slide 1: Corporate Presentation
CORPORATE PRESENTATION JANUARY 2023 CSE: BHSC OTCQB: CNVCF FRANKFURT: 8MV
Slide 2: Forward-looking information
The following presentation contains future looking information based on management expectations. Viewers are cautioned that future looking information is subject to risks and uncertainties including the risk that the company will not achieve its production and sales targets as anticipated or that pr
Slide 3: Intersection of health & wellness, technology & sustainability
INTERSECTION OF HEALTH & _. WELLNESS ~~” TECHNOLOGY & AT THE CUTTING EDGE “le SUSTAINABI LITY
Slide 4: Global leader in plant cell biology
GLOBAL LEADER IN PLANT CELL BIOLOGY
Slide 5: Next generation science-based therapeutics
BY UNLOCKING THE SECRETS OF CELLULAR PLANT BIOLOGY, WE BRING THE WORLD NEXT GENERATION SCIENCE-BASED futuristic THERAPEUTICS WITH A STRONG IP PORTFOLIO ADDRESSING A CURRENT 500 BILLION DOLLAR MARKET
Slide 6: Mother Nature provides active medicinal compounds inefficiently
MOTHER NATURE PROVIDES ACTIVE MEDICINAL COMPOUNDS Resveratrol BUT Cannabinoids Alkaloids MOTHER NATURE PROVIDES THEM INEFFICIENTLY & Flavonoids TECHNOLOGY HAS FAILED TO DELIVER Gossypol Polyphenols INCONSISTENT UNCLEAN HIGH COST DAMAGES THE ENVIRONMENT
Slide 7: Industrial scale platform
OUR BIO-PLANT CELLICITATION TECHNOLOGY IS THE ONLY INDUSTRIAL SCALE PLATFORM 100% CONSISTENCY THAT BRINGS PATENTABLE PLANT BASED THERAPEUTIC SOLUTIONS WHICH: OUR ASEPTIC FIVE • MAINTAIN THE ORIGINAL NATURAL CLEANLINESS C’S LOW COST COMPOUND STRUCTURE (NON-GMO) • ARE FULL SPECTRUM • IS CONSISTENT & R
Slide 8: Delivered on 2022 guidance and 2023 revenue guidance of $17-20 million
DELIVERED ON 2022 GUIDANCE AND 2023 REVENUE GUIDANCE OF $17-20 MILLION PROVIDED $17-20m $10m $9m $7m $6m $5.6m $5m $4m $3m $2.1m $2m $1m $0.4m $- 2020 2021 2022 2023
Slide 9: Consistent growth across USA and Israel markets with one product
CONSISTENT STELLAR GROWTH ACROSS USA AND ISRAEL MARKETS WITH ONE PRODUCT (2 SKU’S) CONSISTANT SALES AND MARKETING CHANNELS IN USA IN ISRAEL This will increase as retention strategies and product market fit matures.
Slide 10: Strategic vision to build a multi-billion dollar biotech company
DEFINED A CLEAR STRATEGIC VISION TO DELIVER OUR ASPIRATION OF BUILDING A MULTI-BILLION $ BIOTECH COMPANY
Slide 11: Botanical-Sphere
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals Pharmaceuticals F&B Pharmaceutical D2C/B2B API & Companies Adjuvants Cannabinoids Mental Health Rx FDA + Polyphenols Health authorities worldwide D2D Eye Health Rx Research Physicians Institutions Olive Cells Clinical Blood Flow Health Rx
Slide 12: Botanical-Sphere
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE PLANT CELL BIOLOGY
Slide 13: Botanical-Sphere: chemical, bio and botanical synthesis
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE CHEMICAL BIO-SYNTHESIS BOTANICAL SYNTHESIS SYNTHESIS SYNTHESIS ARTIFICIAL REPRODUCIBLE AND GMO MULTI-STEP, ENZYME- NON GMO REPRODUCIBLE AND RELIABLE EXECUTION OF CHEMICAL CATALYZED REPRODUCIBLE PROCESS RELIABLE PROCESS OF COMBINING REACTIONS TO OBTAIN ON
Slide 14: Bio-Plant CELLicitation platform technology
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE BIO PLANT CELLICITATION TM PLATFORM TECHNOLOGY ONE TIME THE CELL CELL PROCCESS PLANT ISOLATION BANK PREPETUAL CELL HARVESTING PROPAGATION PRODUCTION DRYING PROCCESS BANK WET CELLS UPSTREAM DOWNSTREAM Patients Bio-Plant CELLicitation Platform Technology B
Slide 15: Botanical-Sphere: cell types
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Red Grapes Cells Olives Cells Pomegranate Cells Cannabinoids Cells BOTANICAL COMPOSITIONS Development & Industrial Scale Production Polyphenols, Anti-oxidants, Cannabinoids, Psychedelic, proteins, etc… Patients Bio-Plant CELLicitation Platform Technology
Slide 16: Botanical-Sphere: clinical studies
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Physicians Clinical Studies BOTANICAL COMPOSITIONS Development & Industrial Scale Production Polyphenols, Anti-oxidants, Cannabinoids, Psychedelic, proteins, etc… Bio-Plant CELLicitation Platform Technology Botanical Synthesis PLANT CELL BIOLOGY
Slide 17: Botanical-Sphere: FDA and health authorities
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE FDA + Health authorities worldwide Physicians Clinical Studies BOTANICAL COMPOSITIONS Development & Industrial Scale Production Polyphenols, Anti-oxidants, Cannabinoids, Psychedelic, proteins, etc… Bio-Plant CELLicitation Platform Technology Botanical Sy
Slide 18: Botanical-Sphere: nutraceuticals
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals F&B D2C/B2B Cannabinoids FDA + Polyphenols Health authorities worldwide D2D Physicians Olive Cells Clinical Red Grape Cells Studies Pomegrenate Cells D2C BOTANICAL COMPOSITIONS Development & Industrial Scale Production Polyphenols, Anti-ox
Slide 19: Botanical-Sphere: pharmaceuticals
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals Pharmaceuticals F&B Pharmaceutical D2C/B2B API & Companies Adjuvants Cannabinoids Mental Health Rx FDA + Polyphenols Health authorities worldwide D2D Eye Health Rx Research Physicians Institutions Olive Cells Clinical Blood Flow Health Rx
Slide 20: Botanical-Sphere: consumers and patients
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals F&B D2C/B2B Cannabinoids FDA + Polyphenols Health authorities worldwide D2D Physicians Olive Cells Clinical Red Grape Cells Studies Pomegrenate Cells D2C BOTANICAL COMPOSITIONS Development & Industrial Scale Production Polyphenols, Anti-ox
Slide 21: Size of prize for VINIA and other polyphenols is enormous
SIZE OF PRIZE FOR VINIA & OTHER POLYPHENOLS IS ENORMOUS CURRENTLY WE PLAY IN APPROX 13% OF REVENUE POOLS. DIETARY SUPPLEMENT US MARKET SIZE: PROFIT MARGIN SOURCE: PERSISTENCE MARKET RESEARCH 2020 DIETARY SUPPLEMENT REPORT $8 Billion $$$$ with CAGR 8%* * PERSISTENCE RESEARCH DEITARY MARKET REPORT 202
Slide 22: VINIA polyphenols and Piceid Resveratrol
Slide 23: VINIA is the first demonstration of CELLicitation technology
VINIA (BASED ON RED GRAPE CELLS) IS THE FIRST DEMONSTRATION OF THE POWER OF OUR CELLICITATION TECHNOLOGY Heart health Supports heart health by Blood pressure improving blood flow and Supports blood pressure delivery of oxygen.* already within normal range Increases dilation of arteries and blood ves
Slide 24: Brand & product strategy: blood flow market leader
BRAND & PRODUCT STRATEGY BLOOD FLOW MARKET LEADER CLINICAL PROOF - WE ARE THE BEST IN THE MARKET Optimize messaging, landing pages, SEO, advertising. Build this across D2C, Amazon, and D2D
Slide 25: Brand & product strategy: educational content
BRAND & PRODUCT STRATEGY EDUCATIONAL CONTENT REAL SCIENCE SHOWN IN EDUCATIONAL AND VISUAL WAYS Teaching people what's happening in their bodies, even if they don't notice an experience. Most supplement companies don't have the science and understanding to build this content. The Science Behind VINIA
Slide 26: Social proof in USA continues to grow
SOCIAL PROOF IN USA CONTINUES TO GROW EXPONENTIALLY (1700 REVIEWS) - BUILDING SIGNIFICANT CREDIBILITY FOR THE VINIA BRAND FEB 12th, 2023 OCT 25th, 2022 JUL 4, 2022 APR 4, 2022 OCT 14, 2021
Slide 27: Significant expansion planned in next 6-12 months
SIGNIFICANT EXPANSION PLANNED IN NEXT 6-12 MONTHS H2, 2023 H1, 2025 CAN 5% UK+EU +6% H1, 2025 JP 9% USA 35% H1, 2023 CH, PH SK 27% CHINA – CROSS BORDER 2023 AND 2024 LOCAL SALES - 2025 Source: Persistence Market Research 2020 Dietary Supplement Report and iimedia for China Market
Slide 28: Botanical-Sphere: direct to doctors
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals Pharmaceuticals F&B Pharmaceutical D2C/B2B API & Companies Adjuvants Cannabinoids Mental Health Rx FDA + Polyphenols Health authorities worldwide Physicians D2D Eye Health Rx Research Physicians Institutions Olive Cells Clinical Blood Flow
Slide 29: Direct to Doctors program targeting 45,000 practitioners
DIRECT TO DOCTORS (D2D) PROGRAM IS TARGETTING 45,000 “PRACTITIONERS” IN THE US INCLUDES DOCTORS, NURSES, “HEALTH COACHES,” CHIROPRACTORS, NUTRITIONISTS, PHYSICAL THERAPISTS, PREVENTION-FOCUSED AND SUPPORTERS OF SUPPLEMENTS & NUTRACEUTICALS
Slide 30: Marketing initiatives to support D2D push
SPECIFIC MARKETING INITIATIVES IN PLACE TO SUPPORT OUR D2D PUSH Dr Brian Cornblatt Chief Medical Officer PODCAST TOUR PARTICIPATING IN SUPPORT D2D WITH FOR DR BRIAN KEY EVENTS KEY PARTNERS
Slide 31: Early success with major strategic customers
WE HAVE ALREADY HAD GREAT EARLY SUCCESS WITH MAJOR STRATEGIC CUSTOMERS
Slide 32: Botanical-Sphere: food and beverage
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals Pharmaceuticals F&B Pharmaceutical F&B Companies D2C/B2B API & Adjuvants Cannabinoids Mental Health Rx FDA + Polyphenols Health authorities worldwide Eye Health Rx Research Physicians Physicians Institutions Olive Cells Clinical Blood Flow
Slide 33: Disrupting the protein bar market
DISRUPTING THE PROTEIN BAR MARKET PROFIT MARGIN PROTEIN+ BAR $$$ US MARKET SIZE: $3 Billion with CAGR 6%* FOR ILLUSTRATION PURPOSE ONLY * POLARIS PROTEIN BAR MARKET RESEARCH REPORT 2022-2030
Slide 34: Category disruptor: dietary supplement protein bar
CATEGORY DISRUPTOR - WE WILL BE THE ONLY DIETARY SUPPLEMENT PROTEIN BAR AVAILABLE DIRECT TO CONSUMERS WHICH HAS HEALTH CLAIMS Calories 210 Calories 230 Protein 15 g Protein 14 g Net Carbs 13 g Fat 10 g Fat 9g Fiber 10 g KEY CLAIMS Fiber 3+ g Sugar 5g Sugar 7g Improves physical energy and mental aler
Slide 35: Disrupting the in-home and at-work coffee market
DISRUPTING THE IN-HOME & AT-WORK COFFEE MARKET US DECAF COFFEE MARKET US MARKET SIZE: $4 Billion PROFIT MARGIN with CAGR >5%* $$$ FOR ILLUSTRATION PURPOSE ONLY `SOURCE: MARKETUS RESEARCH 20 MILLION* 20% FROM TRANSPARENCY MARKET RESEARCH REPORT 2021 &Market.us
Slide 36: Size of decaf prize is significant
SIZE OF DECAF PRIZE IS SIGNIFICANT Whereas 18% of respondents only drink decaf.
Slide 37: Category disruptor: decaf coffee with sustained energy
CATEGORY DISRUPTOR - WE WILL BE THE ONLY DECAF COFFEE WITH THE ABILITY TO PROVIDE SUSTAINED ENERGY VIA INCREASE IN BLOOD FLOW KEY CLAIMS Improves physical energy and mental alertness via the delivery of increased blood flow, oxygen and nutrients to your brain, heart and body 12 HOUR SUSTAINED RELEAS
Slide 38: Botanical-Sphere: pharmaceutical companies
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals Pharmaceuticals Pharmaceutical Pharmaceutical F&B D2C/B2B API & Companies Companies Adjuvants Cannabinoids Mental Health Rx FDA + Polyphenols Health authorities worldwide Eye Health Rx Research Physicians Physicians Institutions Olive Cell
Slide 39: Key indications: eye health
CONDUCT CLINICAL TRIALS FOR OUR BOTANICAL COMPOSITIONS AS API’S FOR DRUG DEVELOPMENT AS WELL AS LEVERAGE FINDINGS FOR POTENTIAL DIETARY SUPPLEMENT DEVELOPMENT KEY INDICATIONS EYE HEALTH OPTIC NEURITIS CARDIOVASCULAR HEALTH RAYNAUD’S DISEASE RED GRAPE CELLS POWDER BRAIN HEALTH ALZHEIMER’S, DEMENTIA S
Slide 40: Key indications: cardiovascular
CONDUCT CLINICAL TRIALS FOR OUR BOTANICAL COMPOSITIONS AS API’S FOR DRUG DEVELOPMENT AS WELL AS LEVERAGE FINDINGS FOR DIETARY SUPPLEMENT DEVELOPMENT KEY INDICATIONS EYE HEALTH OPTIC NEUROTICS CARDIOVASCULAR RAYNAUD’S DISEASE RED GRAPE CELLS POWDER BRAIN HEALTH ALZHEIMER’S, DEMENTIA SKIN HEALTH ECTOP
Slide 41: Key indications: red grape cells powder
CONDUCT CLINICAL TRIALS FOR OUR BOTANICAL COMPOSITIONS AS API’S FOR DRUG DEVELOPMENT AS WELL AS LEVERAGE FINDINGS FOR DIETARY SUPPLEMENT DEVELOPMENT KEY INDICATIONS EYE HEALTH OPTIC NEUROTICS CARDIOVASCULAR HEALTH RAYNAUD’S DISEASE RED GRAPE CELLS POWDER BRAIN HEALTH ALZHEIMER’S, DEMENTIA SKIN HEALT
Slide 42: Key indications: red grape cells powder
CONDUCT CLINICAL TRIALS FOR OUR BOTANICAL COMPOSITIONS AS API’S FOR DRUG DEVELOPMENT AS WELL AS LEVERAGE FINDINGS FOR DIETARY SUPPLEMENT DEVELOPMENT KEY INDICATIONS EYE HEALTH OPTIC NEUROTICS CARDIOVASCULAR HEALTH RAYNAUD’S DISEASE RED GRAPE CELLS POWDER BRAIN HEALTH ALZHEIMER’S, DEMENTIA SKIN HEALT
Slide 43: Similar potential with olive and pomegranate cells
SIMILAR POTENTIAL WITH OLIVE CELLS & POMAGRANATE CELLS ACROSS NUTRACEUTICAL & PHARMA PROFIT PILLARS Q1-2024 Q1-2025
Slide 44: Cannabis: the next frontier
CANNABIS THE NEXT FRONTIER
Slide 45: Botanical-Sphere: cannabinoids
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals Pharmaceuticals Pharmaceutical Pharmaceutical F&B D2C/B2B API & Companies Companies Adjuvants Cannabinoids Mental Health Rx FDA + Polyphenols Health authorities worldwide Eye Health Rx Research Physicians Physicians Institutions Olive Cell
Slide 46: Trichome: massive differentiation
MASSIVE DIFFERENTIATION 93% NATURE TRICHOME 100-200X THE DENSITY OF TRICHOMES VS THE PLANT
Slide 47: Cannabinoid trichomes to focus on key medical indications
BHSC CANNABINOID TRICHOMES TO FOCUS ON KEY MEDICAL INDICATIONS 41% Medical Cannabis Consumers by Medical Condition 29% 29% 18% 17% 11% 10% 10% 9% 8% 8% 7% 7% 7% 5% Anxiety Arthritis Pain Insomnia Migraine Inflam High blood Diabetes Neuropathy Bipolar Asthma Fibro Nausea/ ADD/ Chronic disorders matio
Slide 48: Patients substituting cannabis for prescriptions
BEING USED BY PATIENTS TODAY AS SUBSTITUTE FOR MULTIPLE KEY MEDICAL INDICATIONS Proportion of Cannabis Users Who Have Replaced “Some” or “All” of Their Prescriptions with Cannabis by Current Prescription Type 72% 71% 65% 65% 62% 60% 60% 55% 54% 52% 51% 49% 45% 32% 29% 20% 20% 16% 17% 12% 11% 13% 11%
Slide 49: Sustainability Leadership Award
BioHarvest Sciences WINS The Business Intelligence Group 2022 Sustainability Leadership Award ״By delivering the benefits of plants using a fraction of the energy, water, and land that agriculture would, we see the potential for conserving valuable globbal resources at the game-changing scale ״
Slide 50: Experienced management team
LED BY A HIGH-PERFORMANCE EXPERIENCED MANAGEMENT TEAM Ilan Sobel DR. Yochi Hagay DR. Malkit Azachi Michal Sapir Dr. Brian Cornblatt CEO CTO VP R&D VP Regulation Affairs Chief Med Officer Justin Meiklem Alan Rootenberg Kobi Rosenzweig Jarred Turner Head of IR CFO VP Operations VP of E-Commerce
Slide 51: Supported by a team of industry leaders
SUPPORTED BY A TEAM OF INDUSTRY LEADERS SCIENTIFIC ADVISORY BOARD Gavriel Lambert STEVEN LEHRER DR RHONA APPLEBAUM DR. DENNIS GOODMAN DR. GEORGE GARIBALDI INVESTMENT BANKING VETERAN BIOTECH LEADER REGULATORY AND SCIENTIFIC AFFAIRS CARDIOLOGIST Psychiatrist & Neuro-Scientist SCOTT MCCUNE COL CHRIS HA
Slide 52: Take the power of our technology to new frontiers
TAKE THE POWER OF OUR TECHNOLOGY TO NEW FRONTIERS Produce primary metabolites such as Produce antioxidant compounds that Assess the health impact of 1 premium proteins that are needed to provide required nutrition for humans 2 can help reduce human cellular stress and prevent damage caused by 3 micr
Slide 53: Key highlights
KEY HIGHLIGHTS: Global leader in Plant Cell Biology Innovative and disruptive Biotech Platform Technology opening the gate for patentable Botanical Drugs Validated and proven technology across multiple verticals with significant current revenues High scalability with low capex requirements ($3-4M) a
Slide 54: Bringing the power of the plant kingdom to the people
PURPOSE DRIVEN COMPANY BRINGING THE POWER OF THE PLANT KINGDOM TO THE PEOPLE
BioHarvest Sciences — Investor Presentation (February 2023) on 6ix